This recombinant monoclonal antibody is designed as a research-grade biosimilar to INBRX-106, targeting TNFRSF4 (tumor necrosis factor receptor superfamily member 4), also known as OX40 or CD134. TNFRSF4 is a co-stimulatory receptor expressed primarily on activated T cells that plays a critical role in T cell activation, proliferation, and survival. Upon binding its ligand OX40L, this receptor enhances T cell-mediated immune responses and promotes the differentiation of effector and memory T cells. TNFRSF4 has emerged as an important therapeutic target in immuno-oncology, as its activation can enhance anti-tumor immunity by stimulating cytotoxic T lymphocytes and reducing regulatory T cell suppressive activity.
INBRX-106 is a clinical-stage agonistic antibody engineered to activate TNFRSF4 signaling and enhance T cell responses against tumors. This biosimilar provides researchers with a valuable tool for investigating OX40-mediated immune modulation, studying T cell biology, and exploring combination immunotherapy approaches in preclinical cancer models. It supports investigations into checkpoint modulation and adaptive immunity mechanisms relevant to oncology and autoimmune disease research.
Email: support@cusabio.com
Distributors Worldwide